secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001551152-25-000043
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge
--------------------------------------------------------------------------------

- Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.
- Q3 2025 adjusted EPS guidance revised to $1.74-$1.78 from prior $3.24-$3.28.
- Full-year 2025 adjusted EPS guidance lowered to $10.38-$10.58 from $11.88-$12.08.
- Previously announced FY guidance excluded Q3 IPR&D; further IPR&D beyond Q3 not forecasted.
- Q3 results not finalized; preliminary estimates subject to closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/0001551152-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/abbv-20251003.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer